New Iridium, a company developing commercialized photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $256,000 to conduct research and development work on facilitating timely availability of Remdesivir, a potential life-saving drug in the global fight against COVID-19. This grant funds the development of an optimized manufacturing process for Remdesivir that utilizes photocatalysis, a powerful new chemical technology driven by light rather than heat. If successful, the new process will result in shortened production times and higher yields, providing greater supply to the market more quickly than current manufacturing protocols.Â
Contact CEO and founder Chern-Hooi Lim at chern@newiridium.com for New Iridium related inquiries.